ClinicalTrials.gg
Enrolling by invitationNCT06360874Updated May 30, 2024

A Study to Evaluate Safety, Tolerability and Pharmacokinetic of ND-003 Tablets in Healthy Adults

A Phase 1 interventional study of ND-003 40mg and ND-003 placebo 40mg in Healthy, sponsored by Shenzhen NewDEL Biotech, Co., Ltd. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-30.

Sponsored by Shenzhen NewDEL Biotech, Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate Safety, Tolerability and Pharmacokinetic of ND-003 tablets in Healthy Adults

Read the detailed description

This is a Phase 1, randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability and Pharmacokinetic of of ND-003 in healthy adults volunteers, and then evaluate food effects.

The study will be conducted in three parts: Part A-Single ascending dose (SAD) , Part B-Multiple ascending dose (MAD) and Part C-Food Effect. Each subject will be enrolled in only one cohort of either Parts A or B or C of the study, to receive only one dose regimen during the study.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Shenzhen NewDEL Biotech, Co., Ltd is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Healthy volunteers, both male and female;
    1. age: 18-45 years old;
    1. Weight: Male ≥ 50kg, female ≥ 45kg, 19 ≤ ≤ 26 (BMI=weight (kg)/height2 (m2);
    1. Subject is in generally good health according to physical examination;
    1. Subjects voluntarily participate in clinical trials and sign a written form.

Exclusion criteria

Exclusion Criteria:

    1. Participated in any other clinical trial of drugs within the three months prior to the trial;
    1. Any disease that may affect the safety of the clinical trial or the in vivo process of the drug;
    1. Allergic constitution: If there is a history of drug, food allergies, or skin allergies;
    1. Any drug that inhibits or induces liver metabolism has been used within 28 days prior to the use of the investigational drug;
    1. Have used any medication (including Chinese herbal medicine) and health supplements within 14 days prior to administration;
    1. Have special requirements for diet and cannot follow a unified diet;
    1. Subjects with a history of intolerance to venipuncture blood collection, or fear of needles and hemophobia;
    1. Drinking alcohol, tea, or caffeinated beverages for a long period of time or within 48 hours prior to administration;
    1. Previous alcoholics, or frequent alcohol consumption within 6 months prior to administration; or consumption of any alcohol-containing product within 24 hours prior to administration ;
    1. Blood donation or blood loss (greater than 450 mL) within 3 months prior to administration, or planning to donate blood during the study period or within 3 months after the end of the study ;
    1. Acute illness occurred during pre study screening or prior to administration;
    1. Subjects who have any diet that can alter liver enzymes activity within 24 hours prior to administration;
    1. Have undergone surgery within the first three months of screening, or plan to undergo surgery during the study period;
    1. Previous drug addict and drug abuse;
    1. Smoking more than 5 cigarettes per day within the first 14 days of screening, or unable to withdraw nicotine-containing products during the study;
    1. Subjects who smoke or use nicotine-containing products from screening to hospitalization;
    1. Abnormal and results before screening or administration, or (QTcF - Fridericia's correction formula)>450 msec;
    1. Positive results of nicotine test;
    1. Alcohol breath test, with test results greater than 0.0mg/100 mL;
    1. Positive urine drug test at screening;
    1. Pregnant or lactating women;
    1. Have plan for fertility or reluctance use any during the study period and within 6 months after the end of the trial;
    1. Subjects with other factors that are not suitable for participation in this study as judged by the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    ND-003 40mg

    SAD(Single Ascending Dose) Cohort 1: Participants were orally administered 40mg of ND-003 or matched placebo once.

    Drug: ND-003 40mg · Drug: ND-003 placebo 40mg

  • Experimental
    ND-003 80mg

    SAD Cohort 2: Participants were orally administered 80mg of ND-003 or matched placebo once.

    Drug: ND-003 80mg · Drug: ND-003 placebo 80mg

  • Experimental
    ND-003 160mg

    SAD Cohort 3: Participants were orally administered 160mg of ND-003 or matched placebo once.

    Drug: ND-003 160mg · Drug: ND-003 placebo 160mg

  • Experimental
    ND-003 240mg

    SAD Cohort 4: Participants were orally administered 240mg of ND-003 or matched placebo once.

    Drug: ND-003 240mg · Drug: ND-003 placebo 240mg

  • Experimental
    ND-003 300mg

    SAD Cohort 5: Participants were orally administered 300mg of ND-003 or matched placebo once.

    Drug: ND-003 300mg · Drug: ND-003 placebo 300mg

  • Experimental
    ND-003_Dose 1

    MAD (Multiple Ascending Dose)Cohort 1:The dose of ND-003 or matched placebo will be determined based on the results of the SAD. Three dose cohorts will be set and the volunteers will receive the drug once a day for 7 consecutive days.

    Drug: MAD_ND003_Dose 1 · Drug: MAD_placebo_Dose 1

  • Experimental
    ND-003_Dose 2

    MAD Cohort 2: The dose of ND-003 or matched placebo will be determined based on the results of the SAD. Three dose cohorts will be set and the volunteers will receive the drug once a day for 7 consecutive days.

    Drug: MAD_ND003_Dose 2 · Drug: MAD_placebo_Dose 2

  • Experimental
    ND-003_Dose 3

    MAD Cohort 3:The dose of ND-003 or matched placebo will be determined based on the results of the SAD. Three dose cohorts will be set and the volunteers will receive the drug once a day for 7 consecutive days.

    Drug: MAD_ND003_Dose 3 · Drug: MAD_ placebo_Dose 3

  • Experimental
    Food effect_Cohort 1

    Food effect Cohort 1: The dose of ND-003 tablets will be determined based on the results of the SAD and MAD. Participants will be orally administered in fasting condition in day 1 and then in fed condition in day 8.

    Drug: Food effect_Cohort 1

  • Experimental
    Food effect_Cohort 2

    Food effect Cohort 2: The dose of ND-003 tablets will be determined based on the results of the SAD and MAD. Participants will be orally administered in fed condition in day 1 and then in fasting condition in day 8.

    Drug: Food effect_Cohort 2

Interventions

  • Participants receive 40mg ND-003 tablets once.

  • DrugND-003 placebo 40mg

    Participants receive placebo tablet matching to receive 40mg of ND-003.

  • Participants receive 80mg ND-003 tablets once.

  • DrugND-003 placebo 80mg

    Participants receive placebo tablet matching to receive 80mg of ND-003.

  • Participants receive 160mg ND-003 tablets once.

  • DrugND-003 placebo 160mg

    Participants receive placebo tablet matching to receive 160mg of ND-003.

  • Participants receive 240mg ND-003 tablets once.

  • DrugND-003 placebo 240mg

    Participants receive placebo tablet matching to receive 240mg of ND-003.

  • Participants receive 300mg ND-003 tablets once.

  • DrugND-003 placebo 300mg

    Participants receive placebo tablet matching to receive 300mg of ND-003.

  • DrugMAD_ND003_Dose 1

    Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.

  • DrugMAD_placebo_Dose 1

    Participants will orally administrated the placebo tablets matching to the MAD_ND003_Dose 1

  • DrugMAD_ND003_Dose 2

    Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.

  • DrugMAD_placebo_Dose 2

    Participants will orally administrated the placebo tablets matching to the MAD_ND003_Dose 2

  • DrugMAD_ND003_Dose 3

    Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.

  • DrugMAD_ placebo_Dose 3

    Participants will orally administrated the placebo tablets matching to the MAD_ND003_Dose 3

  • DrugFood effect_Cohort 1

    Firstly orally administrated ND-003 tablets in fast state and then in fed state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.

  • DrugFood effect_Cohort 2

    Firstly orally administrated ND-003 tablets in fed state and then in fast state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.

06

What researchers measure

Primary outcomes

  1. Adverse Events (AE)

    Number and type of participants with treatment-related adverse events

    Time frame: through study completion, an average of 1 month

Secondary outcomes

  1. maximum concentration (Cmax)

    The drug maximum concentration reaches when the absorption rate is equal to the elimination rate at a single dose.

    Time frame: Pre-dose 60 minutes and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96 hours post-dose

  2. Time to maximum concentration (Tmax)

    Time required to reach peak drug concentration after a single administration.

    Time frame: Pre-dose 60 minutes and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96 hours post-dose

  3. Elimination Half-life (t1/2)

    Elimination Half-life (t1/2) refers to the time required to eliminate 50% of the drug from the body.

    Time frame: Pre-dose 60 minutes and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96 hours post-dose

  4. Clearance (CLz/F)

    Clearance (CLz/F) describes how the body effectively eliminate drugs from the systemic circulation, typically defined as the volume of drug-containing plasma eliminated from the body per unit time.

    Time frame: Pre-dose 60 minutes and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96 hours post-dose

  5. AUC from time 0 to last time of quantifiable concentration (AUC0-t)

    Area under the plasma concentration-time curve from the initial administration to the last measurable concentration point.

    Time frame: Pre-dose 60 minutes and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96 hours post-dose

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Dec 2024, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2024
First posted
Apr 11, 2024
StartActual
May 9, 2024
Primary completionEst.
Dec 2024
CompletionEst.
Feb 2025
Last update
May 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06360874
Lead sponsor
Shenzhen NewDEL Biotech, Co., Ltd
Collaborators
Shenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd.
Responsible party
Sponsor
First posted
Apr 11, 2024
Start date
May 9, 2024
Primary completion
Dec 2024 (estimated)
Completion
Feb 2025 (estimated)
Last update
May 30, 2024

Study contacts

Shaojun Shi, PhD
principal investigator · Wuhan Union Hospital, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TRK/RET Inhibitor ND-003

Start the discussion